TG Therapeutics Briumvi Deal Fails To Impress The Market
Shares Down Nearly 50%
Linking up with Germany’s Neuraxpharm to sell the multiple sclerosis drug Briumvi in Europe and elsewhere has gone down badly with investors but the bashing that TG Therapeutics’ shares has taken seems excessive.
